Exagen Inc. (XGN)
- Sector
- Biotechnology
- Last price
- $8.48
- As of
Kresmion compiles this page from XGN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
EXAGEN INC. (XGN): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-04.
See the full XGN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for XGN on one page. Preview it with sample data, then open it live with a free account.
Preview the XGN dossierActive signals for XGN
- highCONSENSUS_SELL
3 tracked funds reduced XGN this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 81% of XGN (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 62% of XGN (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 32.3%, EPS $-0.13 vs $-0.1919 estimate
- highCONSENSUS_SELL
3 tracked funds reduced XGN this 2026Q1 - institutional consensus
FREE, NO ACCOUNT
Every signal on XGN, as it fires
You are seeing 5 of 11 signals recorded on XGN since 2026-05-26.
The five above landed across 4 days. The other 6 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in XGN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 30068X103 · 2026Q2 | $279K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 30068X103 · 2026Q2 | $231K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 30068X103 · 2026Q2 | $184K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 30068X103 · 2026Q2 | $67K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, XGN
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
XGN against its peers
XGN's operating margin of -21.1% ranks in the 82nd percentile of 19 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | XGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 66.6M USD | 21.0M USD | 75 | 17 |
| Revenue YoY | n/a | -15.9% | n/a | 5 |
| Gross margin | 58.3% | n/a | n/a | 4 |
| Operating margin | -21.1% | -273.1% | 83 | 19 |
| Net margin | -30.0% | -233.7% | 79 | 20 |
| Return on equity | -114.3% | -65.8% | 30 | 21 |
| 1 year | -23.2% | -14.0% | 36 | 17 |
Peers (24): ACOG, IVVD, RNAC, NAGE, ELDN, TRDA, ALEC, PRQR, PLX, LYEL, CGEN, MGNX, CUE, PYXS, CAMP, IFRX, STRO, SION, NGEN, IPHA, SLGL, ORMP, GLSI, FATE. Left out: VRXA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (XGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow XGN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XGN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.